CTNI-16. TROTABRESIB (CC-90010, BMS-986378), A REVERSIBLE, POTENT ORAL BROMODOMAIN AND EXTRATERMINAL INHIBITOR (BETi) IN PATIENTS WITH HIGH-GRADE GLIOMAS: A PHASE 1 OPEN-LABEL ‘WINDOW OF OPPORTUNITY’ STUDY

Authors: Michael Vogelbaum, Juan Manuel Sepulveda, David Reardon, Bishoy Hanna, Ellen Filvaroff, Ida Aronchik, Barbara Amoroso, Marlene Zuraek, Tania Sanchez-Perez, Cristina Mendez, Zariana Nikolova, Victor Moreno

Published: 2021-11-18

DOI: 10.1093/neuonc/noab196.241

Source: Full article

CTNI-16. TROTABRESIB (CC-90010, BMS-986378), A REVERSIBLE, POTENT ORAL BROMODOMAIN AND EXTRATERMINAL INHIBITOR (BETi) IN PATIENTS WITH HIGH-GRADE GLIOMAS: A PHASE 1 OPEN-LABEL ‘WINDOW OF OPPORTUNITY’ STUDY

Abstract